{
  "@context": "https://orbyd.app/schemas/dossier.v1.json",
  "ticker": "XENE",
  "name": "Xenon Pharmaceuticals Inc.",
  "url": "https://orbyd.app/dossiers/XENE/",
  "json_url": "https://orbyd.app/dossiers/XENE.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "graded_conviction": null,
  "archetype": {
    "code": "a5",
    "n": 5
  },
  "current_thesis": "Post-X-TOLE2 de-risking (2026-03-09, placebo-adjusted -42.7%, p≈6e-12) already re-rated azetukalner from the $40s to new all-time-high closes near $71. The story is now maturing into a procedural Q3 2026 NDA, with the next true binary (X-NOVA2 MDD) not until H1 2027 and the ~Aug 10 Q2 print a blackout — a fresh chase at highs lacks a near-term accelerant.",
  "invalidation_trigger": "A weekly close below $62 breaks the post-X-TOLE2 consolidation base and signals the March de-risking re-rate is unwinding; compounded if the FOS NDA slips out of Q3 2026 or draws an FDA refuse-to-file.",
  "catalyst_date": "2026-08-10",
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "precision-biotech-therapeutics"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Kv7 comp Biohaven (BHVN) BHV-7000 cut to Underperform by BofA 2026-06-29; track as read-through peer.",
    "Big epilepsy de-risking catalyst already fired 2026-03-09; momentum leg is realized, not pending.",
    "Q2 2026 earnings ~2026-08-10 (est.; Q1 reported 2026-05-07) — brief blackout risk around the print; thesis is not earnings-driven.",
    "FOS NDA guided to Q3 2026 (no firm date); a slip is the key near-term negative surprise. US launch targeted late 2027/early 2028 pending FDA + DEA scheduling.",
    "Cash $1,339.6M at 2026-03-31 (incl. $837.6M raise), runway into 2029 — no near-term dilution overhang.",
    "Consensus Buy, avg PT $77.20 (2026-07-25); JPM Overweight $82 (2026-05-27); Needham Buy $78 (2026-05-08). Spot near/above avg PT at all-time-high closes.",
    "Kv7 comp Biohaven (BHVN) BHV-7000 cut to Underperform by BofA 2026-06-29 — track as read-through peer.",
    "Big epilepsy de-risking catalyst already fired 2026-03-09; momentum leg is realized. Price making new ATH closes (70.96 on 2026-07-09, 52-wk high 72.66) but on a maturing narrative, no MA pullback."
  ],
  "body_markdown": "## Current Thesis\nThe epilepsy binary that defined this name resolved to the upside on 2026-03-09, when Phase 3 X-TOLE2 of azetukalner (a Kv7 potassium-channel opener) hit hard in focal onset seizures: 25 mg median seizure-frequency reduction of -53.2% vs -10.4% placebo, placebo-adjusted -42.7% (p≈6e-12), described by the company as best-in-class for the indication. That print re-rated the stock from the low-$40s and has since carried it to fresh all-time-high closes (70.96 on 2026-07-09; 52-week high 72.66, +102% over one year). What is left to buy today is a de-risked, cash-rich CNS platform grinding into a procedural Q3 2026 NDA, with the next genuine binary — X-NOVA2 in major depressive disorder — not due until H1 2027. The accelerating leg is realized; the tape is now a maturing story digesting one catalyst while it waits ~6-9 months for the next, with an August earnings blackout in the near path.\n\n## Bull Case\n- **De-risked lead asset**: X-TOLE2 topline (2026-03-09) met primary endpoint in both arms — 25 mg MPC -53.2% vs placebo -10.4% (p≈6e-12), 15 mg -34.5% (p=0.00007). Placebo-adjusted -42.7% exceeds the prior Phase 2b X-TOLE and is best-in-class efficacy per the company.\n- **Regulatory path live**: FOS NDA submission guided to Q3 2026; standard FDA review plus DEA scheduling implies a US launch targeted for late 2027 / early 2028 (Q1 call 2026-05-07, May 2026 corporate overview).\n- **Fortress balance sheet**: $1,339.6M cash and marketable securities at 2026-03-31 (includes an $837.6M post-data raise), funding operations into 2029 — full Phase 3 program plus commercial build with no near-term dilution overhang.\n- **MDD second leg**: X-NOVA2 Phase 3 topline in MDD expected H1 2027, X-NOVA3 ongoing; a non-monoaminergic mechanism into a TAM that dwarfs epilepsy, and the optionality underwriting the ~$6.9B cap on a pre-revenue asset.\n- **Sell-side aligned**: consensus Buy across 17 analysts (14 buy, 2 strong buy, 1 sell), average PT $77.20 as of 2026-07-25; JPMorgan Overweight PT $82 (2026-05-27);\n- **Competitor stumble**: Biohaven's Kv7 rival BHV-7000 was cut to Underperform by BofA on 2026-06-29 ahead of its own epilepsy data — the clean Phase 3 win in this mechanism class already sits here.\n- **Pipeline breadth**: bipolar depression (X-CEED), primary generalized tonic-clonic seizures (X-ACKT), and Phase 1 pain assets XEN1701 (NaV1.7) / XEN1120 (Kv7) reading out H2 2026.\n- **Trend intact**: price is making new all-time-high closes rather than rolling over, +102% over one year and ~+35% YTD — momentum has not broken.\n\n## Bear Case\n- The catalyst that mattered is behind the tape. Near ~$71 the market cap is ~$6.9B for a company with zero product revenue and a launch no earlier than late 2027.\n- Catalyst gap: the next hard binary (X-NOVA2 MDD) is H1 2027, leaving 6-9 months where an already-priced NDA submission is the only event of substance.\n- Burn is climbing: Q1 2026 net loss $102.3M vs $65.0M a year earlier as commercial preparation ramps.\n- MDD is a high-placebo, high-failure indication. X-NOVA2/3 are truly un-de-risked; a miss removes the premium leg of the thesis.\n- The adjunctive-epilepsy market is crowded and generic-heavy, and an active Kv7 competitor keeps commercial-execution risk live even behind best-in-class data.\n- The March vertical has cooled to a grind. A name that already doubled off a resolved catalyst is a late-tape entry, not an accelerating narrative firing fresh.\n- The ~2026-08-10 Q2 print injects near-term binary noise into a thesis that is not earnings-driven.\n\n## Setup & Price Structure\n- Spot near the highs: all-time-high close $70.96 (2026-07-09), 52-week high $72.66, 52-week low $30.00; ~+102% over one year, ~+35% YTD. Market cap ~$6.9B.\n- The re-rate off 2026-03-09 data ran the stock from the low-$40s; it consolidated roughly $65-75 and then pushed to new closing highs in early July.\n- The $837.6M secondary added float but removed dilution risk into 2029.\n- The multi-month base floor sits near $64-65; a weekly close below $62 clears the entire post-data range and would signal the re-rate unwinding.\n- There has been no recent pullback to moving-average support — any entry here is at-highs, into an approaching earnings blackout, without a fresh accelerant. That is a stand-aside for a momentum book unless the story re-accelerates.\n\n## Catalyst Calendar (next 30 days)\n- **~2026-08-10 (est.)**: Q2 2026 financial results and business update — earnings blackout risk and the primary near-term dated event (est. per investing.com/Nasdaq calendars; Q1 reported 2026-05-07).\n- **Q3 2026 (no firm date)**: FOS NDA submission to the FDA — procedural and largely priced; a slip out of the quarter is the key negative surprise to watch.\n- **H2 2026 (no firm date)**: Phase 1 pain readouts XEN1701 (NaV1.7) and XEN1120 (Kv7) — smaller optionality, unlikely to move the tape alone.\n- (The next true binary, X-NOVA2 MDD topline, is H1 2027 — outside this window.)\n\n## What Would Change Our Mind\n- A weekly close below $62 breaks the post-X-TOLE2 consolidation base and marks the March de-risking re-rate unwinding — the level that turns this from a hold-and-watch into a broken structure.\n- The FOS NDA slipping out of Q3 2026, or drawing an FDA refuse-to-file, removes the only near-term positive and reprices the regulatory timeline.\n- A negative X-NOVA2 MDD readout (H1 2027) would strip out the premium optionality that justifies the current multiple, though that sits far outside the trading window.\n- Kv7 class read-through: strong epilepsy data from Biohaven's BHV-7000 would narrow the \"clean Kv7 winner\" differentiation and pressure the commercial narrative.\n- Re-acceleration setup: a decisive breakout and hold above the $72.66 52-week high on expanding volume, or a positive pipeline/MDD surprise, would flip the read back toward accelerating and justify a fresh chase.\n\n## Correlation Notes\n- **Direct peer**: Biohaven (BHVN) — the closest Kv7/epilepsy mechanism read-through; BofA Underperform 2026-06-29 is a negative for the class narrative but a relative positive for XENE's competitive position.\n- **Sector beta**: trades with SMID-cap biotech risk appetite (XBI) and is a long-duration, rate-sensitive pre-revenue name — hawkish macro compresses the multiple independent of pipeline news.\n- **Idiosyncratic dominance**: single-asset concentration in azetukalner means clinical and regulatory headlines override macro around catalyst dates, keeping index correlation low into events.\n- **Franchise read-through**: X-NOVA MDD data will be read across novel-mechanism depression names, making those moves a forward tell for how the Street prices XENE's second leg.\n\n## Sources\n- [MacroTrends — XENE price history](https://www.macrotrends.net/stocks/charts/XENE/xenon-pharmaceuticals/stock-price-history)\n- [Xenon — Q1 2026 results & business update](https://investor.xenon-pharma.com/news-releases/news-release-details/xenon-reports-q1-2026-financial-results-and-provides-business)\n- [Xenon — Phase 3 X-TOLE2 topline](https://investor.xenon-pharma.com/news-releases/news-release-details/xenon-announces-positive-topline-data-phase-3-x-tole2-study)\n- [Daily Political — XENE consensus PT $77.20 (2026-07-25)](https://www.dailypolitical.com/2026/07/25/brokerages-set-xenon-pharmaceuticals-inc-nasdaqxene-price-target-at-77-20.html)",
  "first_seen": "2026-07-10",
  "last_analyzed": "2026-07-26T12:45:42+00:00",
  "last_synthesized": "2026-07-26",
  "last_update_source": "watchlist_research",
  "license": "Content © orbyd. Cite the canonical URL."
}